Type 2 Diabetes

Advertisement
Patrick DalyAtherosclerotic Disease | April 11, 2023
According to Silvia Giovannini and colleagues from the Università Cattolica del Sacro Cuore in Rome, Italy, recent ...
Read More
Patrick DalyAtrial Fibrillation | April 7, 2023
Researchers led by Chisa Matsumoto conducted a randomized controlled trial to evaluate the incidence of atrial ...
DocWire News EditorsHypertension | May 2, 2023
More than one drink in patients with type 2 diabetes is associated with increased hypertension, a new study suggests. ...
DocWire News EditorsCardiology | April 6, 2023
Metformin was associated with a reduction in all-cause mortality, but not a composite study endpoint, in high-risk ...
DocWire News EditorsCardiology | April 6, 2023
The inhibition of SGLT-2 was not associated with an improvement in left ventricular (LV) reverse remodeling in patients ...
DocWire News EditorsAHA Scientific Sessions 2018 | November 19, 2018
Stephen D. Wiviott, MD, talks with DocWire News, about the results and implications from the Dapagliflozin Effect on ...
DocWire News EditorsAHA Scientific Sessions 2018 | April 11, 2023
Empagliflozin, an SGLT2 inhibitor, significantly reversed left ventricular (LV) remodeling in a population of diabetic ...
Kaitlyn D’OnofrioCardiology | September 12, 2023
A recent study found an association between physical activity (PA) and a decreased risk of type 2 diabetes and ...
DocWire News EditorsCardiology | April 6, 2023
Albiglutide was superior to placebo for the reduction of major adverse cardiac events (MACE) in patients with type ...
DocWire News EditorsCardiology | April 6, 2023
Canagliflozin, a sodium glucose cotransporter 2 inhibitor, reduced the risk of cardiovascular (CV) death ...
DocWire News EditorsACC 2018 Conference | April 6, 2023
An analysis of a subset of patients from the CANTOS trial suggested that canakinumab does not prevent prediabetes from ...
Advertisement
Advertisement